| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDSN |
| Uniprot No | Q15517 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 442-529aa |
| 氨基酸序列 | KIILQPCGSKSSSSGHPCMSVSSLTLTGGPDGSPHPDPSAGAKPCGSSSA GKIPCRSIRDILAQVKPLGPQLADPEVFLPQGELLNSP |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDSN(Corneodesmosin)重组蛋白的模拟参考文献示例，涵盖不同研究方向：
---
1. **文献名称**：*Structural and functional characterization of recombinant human corneodesmosin*
**作者**：Serre, G., et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组CDSN蛋白，并利用X射线晶体学解析其三维结构。实验表明，重组CDSN在体外可促进角质细胞粘附，揭示了其在皮肤屏障功能中的关键作用，为遗传性角质化疾病(如Netherton综合征)的机制研究提供依据。
2. **文献名称**：*Autoantibodies against corneodesmosin in psoriasis: Role of recombinant CDSN in immune response*
**作者**：Akiyama, M., et al.
**摘要**：通过ELISA和免疫印迹分析，发现银屑病患者血清中CDSN特异性自身抗体水平显著升高。利用重组CDSN蛋白验证了其与T细胞反应的关联，提示其在银屑病病理中的潜在免疫调节作用，为靶向治疗提供新思路。
3. **文献名称**：*Recombinant corneodesmosin as a therapeutic agent for skin repair*
**作者**：Jonca, N., et al.
**摘要**：研究评估了重组CDSN蛋白在小鼠皮肤损伤模型中的修复效果。结果显示，局部应用重组CDSN可加速表皮再生并减少炎症反应，表明其在慢性伤口愈合中的潜在临床应用价值。
4. **文献名称**：*Mutations in CDSN disrupt protein interactions revealed by yeast two-hybrid assay*
**作者**：Hovnanian, A., et al.
**摘要**：通过酵母双杂交系统，分析了遗传性掌跖角化病相关CDSN突变体与桥粒蛋白的结合能力。重组突变体CDSN显示结合活性显著降低，阐明了基因变异导致皮肤脱屑的分子机制。
---
注：以上文献为示例性内容，实际引用时需以真实发表的论文为准。建议通过PubMed、Web of Science等数据库检索关键词“corneodesmosin recombinant”获取最新研究。
**Background of Recombinant CDSN Protein**
CDSN (Corneodesmosin) is a key protein involved in maintaining epidermal integrity and skin barrier function. Primarily expressed in the granular and cornified layers of the epidermis, it plays a critical role in keratinocyte adhesion and desquamation by integrating into corneodesmosomes—specialized structures that bind adjacent corneocytes. Genetic mutations or dysregulation of CDSN are linked to skin disorders such as psoriasis, hypotrichosis simplex, and peeling skin syndrome, underscoring its importance in dermatological health.
The development of recombinant CDSN protein emerged to address challenges in studying its molecular mechanisms and therapeutic potential. Traditional extraction of native CDSN from tissues is inefficient due to low abundance and complexity. Recombinant technology enables scalable production by inserting the CDSN gene into expression systems (e.g., bacterial, mammalian, or insect cells), followed by purification. This approach ensures high purity, consistency, and reduced immunogenicity for experimental or clinical use.
Recombinant CDSN is widely utilized in research to investigate skin biology, disease pathogenesis, and drug screening. It aids in elucidating interactions with proteases like kallikreins, which degrade corneodesmosomes during desquamation. Additionally, it holds promise for therapeutic applications, such as developing topical treatments to modulate skin barrier repair or targeting autoimmune responses in psoriasis.
Despite advancements, challenges remain, including optimizing post-translational modifications (e.g., glycosylation) to mimic native CDSN and ensuring stability in formulations. Ongoing studies focus on refining expression systems and exploring engineered variants to enhance functionality. Overall, recombinant CDSN represents a vital tool bridging dermatological research and translational medicine.
×
